Latest Breaking News On - Potential milestones - Page 1 : comparemela.com

Akeso to Present at the 42nd Annual J P Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

HONG KONG, Jan. 8, 2024 /PRNewswire/ Akeso, Inc. today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the.

San franciscoUnited statesHong kongMichelle xiaChinese centerAkeso incHealthcare conferenceClinical dataMilestone outlookResponse rateControl rateNear term milestonesDrug evaluationPotential milestonesSummit therapeuticsMain board

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSean mccarthyMarcia belvinStephanie ascherChris ogdenBristol myers squibbCompany prioritiesDevelopment dayBristol myers squibb researchSociety for immunotherapyCompany probodyCompany annual report on formCytomx therapeutics incProvides businessAnnual worldQuarter business highlights

CytomX Therapeutics Reports Third Quarter 2023 Financial

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC).

United statesStephanie ascherChris ogdenMarcia belvinSean mccarthyCompany probodySociety for immunotherapyBristol myers squibbDevelopment dayCompany annual report on formCytomx therapeutics incCompany prioritiesBristol myers squibb researchAnnual worldQuarter business highlightsCytomx therapeutics

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C Announced.

United statesNoord hollandMichael davidsonMatthew philippeHannah deresiewiczCompany phaseNeither the companyNewamsterdam pharma companyExchange commissionDevelopment rd expensesNational lipid associationCompany contactCompany optionsClinical development updatesNewamsterdam pharma companynv nasdaqChief executive officer

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Roy.

United statesUnited kingdomCity ofJen robinsonMiroslava minkovaHeather nicholsAshlea kosikowskiDavid altshulerSekar kathiresanManisha paiGlobal researchVertex pharmaceuticals incorporatedVerve therapeutics incExchange commissionVertex pharmaceuticals incorporated nasdaqUpfront payment